Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 6
2021 2
2022 3
2023 3
2024 1
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women.
Garrido-Cano I, Tapia M, Carbonell J, Peña C, Torres-Ruiz S, Ágreda-Roca A, Lameirinhas A, Tebar C, Burgués O, Hernando C, Lluch A, Brasó-Maristany F, Prat A, Bermejo B, Martínez MT, Cejalvo JM. Garrido-Cano I, et al. Among authors: lameirinhas a. Cancer Commun (Lond). 2025 Jul;45(7):789-793. doi: 10.1002/cac2.70019. Epub 2025 Apr 10. Cancer Commun (Lond). 2025. PMID: 40207642 Free PMC article. No abstract available.
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.
Torres-Ruiz S, Garrido-Cano I, Lameirinhas A, Burgués O, Hernando C, Martínez MT, Rojo F, Bermejo B, Tapia M, Carbonell-Asins JA, Peña CJ, Lluch A, Cejalvo JM, Tormo E, Eroles P. Torres-Ruiz S, et al. Among authors: lameirinhas a. Cell Death Discov. 2024 Aug 22;10(1):372. doi: 10.1038/s41420-024-02128-7. Cell Death Discov. 2024. PMID: 39174500 Free PMC article.
MicroRNAs as a clue to overcome breast cancer treatment resistance.
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. Garrido-Cano I, et al. Among authors: lameirinhas a. Cancer Metastasis Rev. 2022 Mar;41(1):77-105. doi: 10.1007/s10555-021-09992-0. Epub 2021 Sep 15. Cancer Metastasis Rev. 2022. PMID: 34524579 Free PMC article. Review.
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.
Tapia M, Hernando C, Martínez MT, Burgués O, Tebar-Sánchez C, Lameirinhas A, Ágreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Lluch A, Bermejo B, Eroles P. Tapia M, et al. Among authors: lameirinhas a. Cancers (Basel). 2023 Sep 12;15(18):4522. doi: 10.3390/cancers15184522. Cancers (Basel). 2023. PMID: 37760491 Free PMC article. Review.
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.
Torres-Ruiz S, Tormo E, Garrido-Cano I, Lameirinhas A, Rojo F, Madoz-Gúrpide J, Burgués O, Hernando C, Bermejo B, Martínez MT, Lluch A, Cejalvo JM, Eroles P. Torres-Ruiz S, et al. Among authors: lameirinhas a. Int J Mol Sci. 2023 Feb 10;24(4):3601. doi: 10.3390/ijms24043601. Int J Mol Sci. 2023. PMID: 36835014 Free PMC article.
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy.
Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez JF, Candela-Noguera V, Lluch A, Bermejo B, Sancenón F, Cejalvo JM, Martínez-Máñez R, Eroles P. Garrido-Cano I, et al. Among authors: lameirinhas a. ACS Appl Mater Interfaces. 2023 Aug 16;15(32):38323-38334. doi: 10.1021/acsami.3c07541. Epub 2023 Aug 7. ACS Appl Mater Interfaces. 2023. PMID: 37549382 Free PMC article.
20 results